Drug Safety

Adverse Effects Side Effects Regulatory Affairs Toxicology Tianeptine FDA Regulatory Actions Clinical Trials Counterfeit Medications Substance Abuse

Pfizer’s Oral Drug Shows Strong Phase 3 Results in Nonsegmental Vitiligo

The company says the medicine delivered meaningful facial and total-body repigmentation and will pursue regulatory approval for adult patients.

FDA Clears First Generic Flovent HFA Inhaler as Glenmark Prepares U.S. Launch

Utah Panel Advances Kratom Ban as Lawmakers Split on Regulation

Sanofi Pushes Amlitelimab Toward 2026 Filings After Mixed Phase 3 Readouts

Sanofi Ends PPMS Bid After Tolebrutinib Fails Phase 3 as FDA Delays Review for nrSPMS

Bristol Myers Delays ADEPT-2 Alzheimer’s Psychosis Readout to 2026 After Site Irregularities

Ventyx’s NLRP3 Drug Cuts Inflammation Markers in Phase 2, Shares Soar

Graph AI Raises $3 Million Seed Led by Bessemer to Automate Drug Safety

FDA Approves Weekly Leqembi Autoinjector for At-Home Maintenance in Early Alzheimer’s

Ozempic MDL Reaches 2,190 Cases as Regulators Order Broader Warnings

Novartis Ianalumab Meets Efficacy and Safety Goals in Phase 3 Sjögren’s Trials

India Detects Over 3,000 Substandard Drugs in Latest Annual Tests

FDA Names George Tidmarsh Director of Center for Drug Evaluation and Research

Eli Lilly’s Oral Pill Matches Injectable GLP-1 Drugs in Phase 3 Diabetes Trials

Plymouth Investigates Three Linked Drug Deaths Tied to Blue Pills

Alzheimer's Drug Shows Promise for Life-Saving Emergency Use

FDA Alerts Consumers to Recalled Mushroom Chocolates Still on Shelves

U.S. Moves to Reclassify Marijuana, Potentially Easing State Legalization Efforts

CDC Warns of Health Risks from 'Gas Station Heroin' Tianeptine Products

FDA Warns Against 'Gas Station Heroin'; Bipartisan Legislation Introduced to Crack Down on Tianeptine